Brian Park, PharmD

Drug Information Specialist https://www.dermatologyadvisor.com

Brian Park, PharmD, is a Drug Information Specialist at MPR. A graduate of the Ernest Mario School of Pharmacy, Rutgers University, Brian worked as a pharmacy manager at Stop & Shop Pharmacy for 8 years. He is a certified diabetes care pharmacist.

All articles by Brian Park, PharmD

General Medicine

Nalmefene HCl Injection Now Available for Opioid Overdose Treatment

Brian Park, PharmD

June 27, 2022

Pharmacodynamic studies have shown that nalmefene has a longer duration of action than naloxone.

General Medicine

Imcivree Approved for Weight Management in Bardet-Biedl Syndrome

Brian Park, PharmD

June 23, 2022

Imcivree is a melanocortin 4 receptor (MC4R) agonist that re-establishes MC4 receptor pathway activity to reduce hunger and promote weight loss.

General Dermatology

Olumiant Approved for Severe Alopecia Areata

Brian Park, PharmD

June 21, 2022

The approval was based on data from the phase 2/3 BRAVE-AA1 and phase 3 BRAVE-AA2 trials, which included adults with severe alopecia areata.

General Medicine

Oral Treatment Radicava ORS Now Available for Patients With ALS

Brian Park, PharmD

June 17, 2022

The oral suspension can be administered by mouth or via feeding tube using a 5mL oral syringe that comes with the product.

Dermatitis

Roflumilast Foam Looks Promising in Seborrheic Dermatitis Trial

Brian Park, PharmD

June 14, 2022

Roflumilast is a highly potent and selective phosphodiesterase type 4 inhibitor.

Dermatitis

Improvements in Skin Clearance Maintained With Lebrikizumab in Atopic Dermatitis Trials

Brian Park, PharmD

June 10, 2022

The ADvocate 1 and ADvocate 2 trials evaluated lebrikizumab as monotherapy in patients aged 12 years and older weighing at least 40kg with moderate to severe atopic dermatitis.

Rosacea

Epsolay Cream Now Available for Rosacea

Brian Park, PharmD

June 8, 2022

Epsolay is a topical cream that utilizes a patented technology process to encapsulate benzoyl peroxide 5% within silica-based microcapsules.

General Dermatology

Dupilumab Gets Priority Review for Prurigo Nodularis

Brian Park, PharmD

June 2, 2022

The sBLA is supported by data from the phase 3 PRIME2 and PRIME trials that assessed dupilumab in patients 18 years of age and older with prurigo nodularis.

General Medicine

FDA to Review Intranasal Zavegepant for Migraine Treatment

Brian Park, PharmD

June 1, 2022

The NDA submission includes data from 2 pivotal studies that evaluated zavegepant in adults with at least a 1-year history of migraine and migraine attacks.

General Dermatology

Significant Hair Regrowth Observed With Investigational JAK Inhibitor in Alopecia Areata Trial

Brian Park, PharmD

May 25, 2022

The THRIVE-AA1 trial included adults aged 18 to 65 years with moderate to severe alopecia areata who had at least 50% scalp hair loss.

Next post in General Dermatology